← Trials/Trial dossier/NCT02829502

EGRABIS1

UnknownPhase 2

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke

The Effect of Glucagon-like Peptide 1 (GLP-1) Receptor Agonist on Cerebral Blood Flow Velocity in Stroke Patients

Lead sponsor

Christina Kruuse

Assets

Exenatide / GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Stroke

Key I/E criterion

—

Primary endpoint

•Changes in the mean flow velocity in the middle cerebral arteries

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02829502

Org study IDH-16022538

Secondary ID2016-001219-18

Timeline

Milestones

Study first posted2016-07-12estimated

Last update posted2023-03-03actual

Study start2016-08 (month precision)

Primary completion2023-08estimated (month precision)

Study completion2023-11estimated (month precision)

Assets

Investigational agents

Exenatide GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Stroke

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Patients ≥ 18 years with newly symptoms of stroke

•Able to receive exenatide/placebo within 21 days after onset of symptoms

•Radiological confirmed diagnoses of ischemic stroke

•NIHSS between 1-20 at the onset of symptoms

•modified rankin scale (mRS) ≤ 2 prior to onset of symptoms

•Has given written informed consent

Exclusion criteria

•Intracerebral haemorrhage

•Subdural / epidural hemorrhage

•Subarachnoid haemorrhage

•Previously major structural damage to the brain

•Diabetes type 1

•Diabetes type 2

•Known atrial fibrillation

•> 50% stenosis of internal carotid

•Known allergy to GLP-1 receptor agonists

•Hepatic impairment (ALT> 3 x upper normal limit)

•Renal impairment (eGFR <30 ml / min)

•Inflammatory bowel disease

•Previous pancreatitis

•Heart failure (NYHA class 3-4)

•Pregnancy or lactation

•Patient unable to co-operate to the investigation procedures

•Visualization of the middle cerebral artery bilaterally by transcranial dopple not possible

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Cardiometabolic biomarkers

4 endpoints

Primary/protocol endpoint/low confidence

Changes in the mean flow velocity in the middle cerebral arteries and in cortical oxigination.

Time frame:Up till 3 hours

change from baseline, improvement

Secondary/protocol endpoint

Endothelial reactivity

Time frame:3 hours

change from baseline, improvement

Secondary/protocol endpoint

Changes in endothelial biomarkers in blood

Time frame:3 hours

change from baseline, improvement

Secondary/protocol endpoint

Endothelial function/response in ankle-brachial index

Time frame:3 hours

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.